A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.

A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

Variant phenylalanine hydroxylase polypeptides having substitutions at selected amino acid residues are disclosed. Also disclosed are methods of using variant phenylalanine hydroxylase polypeptides, or polynucleotides encoding variant phenylalanine hydroxylase polypeptides, to treat disorders such as phenylketonuria.

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

The present invention relates to a process for the preparation of a dispersion comprising an inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form in an aqueous carrier liquid, the process comprising the steps of a) providing a mixture comprising —the inhalable immunosuppressive macrocyclic active ingredient; —a membrane-forming substance selected from the group of phospholipids; —a solubility-enhancing substance selected from the group of non-ionic surfactants; —optionally one or more excipients; and —the aqueous carrier liquid; b) dispersing the mixture as provided in step a) to form an intermediate aqueous dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in the aqueous carrier liquid; and c) homogenizing the intermediate aqueous dispersion as formed in step b) to form the dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form.

The present invention relates to a process for the preparation of a dispersion comprising an inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form in an aqueous carrier liquid, the process comprising the steps of a) providing a mixture comprising —the inhalable immunosuppressive macrocyclic active ingredient; —a membrane-forming substance selected from the group of phospholipids; —a solubility-enhancing substance selected from the group of non-ionic surfactants; —optionally one or more excipients; and —the aqueous carrier liquid; b) dispersing the mixture as provided in step a) to form an intermediate aqueous dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in the aqueous carrier liquid; and c) homogenizing the intermediate aqueous dispersion as formed in step b) to form the dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form.